# FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer

Source: https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/  
OnCo record `paper-flaura2-long-term-safety-lung-cancer-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Side effects of the osimertinib plus chemotherapy combination were most frequent in the first four chemotherapy cycles and fell steadily once patients moved to maintenance and then to osimertinib alone; few had to stop osimertinib because of them.

## Summary

Post hoc longitudinal safety analysis of the combination arm of FLAURA2, the phase 3 trial in which adding platinum-pemetrexed to first-line osimertinib improved survival over osimertinib alone in EGFR-mutated advanced non-small-cell lung cancer. Adverse events were analysed by each patient's exposure to three treatment periods: induction with the triple combination (276 patients), pemetrexed maintenance with osimertinib (201) and osimertinib alone after pemetrexed stopped (206).

Median durations of the three periods were 2.8, 12.4 and 17.8 months. Onset of any-grade and grade 3 or worse treatment-related adverse events was highest during induction (93 percent and 43 percent), lower during pemetrexed maintenance (90 percent and 25 percent) and lowest on osimertinib alone (58 percent and 14 percent). New haematological, gastrointestinal and skin or nail events, mostly grade 1 or 2, clustered in induction; renal events were more frequent during pemetrexed maintenance (19 percent, all grade 1 or 2) than induction (7 percent). Adverse events leading to osimertinib discontinuation were 8 percent or fewer in every period.

## Fields

- Kind: Key paper
- Last checked: 2026-09-21
- Journal: Lung Cancer
- Year: 2026
- DOI: 10.1016/j.lungcan.2026.109588
- Authors: Planchard D, Jänne PA, Yang JC, et al.
- Findings: Grade 3 or worse treatment-related adverse events began in 43 percent of patients during induction, 25 percent during pemetrexed maintenance and 14 percent during osimertinib alone.; Median duration of the induction, pemetrexed-maintenance and osimertinib-only periods was 2.8, 12.4 and 17.8 months.; Renal adverse events were more frequent during pemetrexed maintenance (19 percent, all grade 1 or 2) than during induction (7 percent); osimertinib discontinuation for adverse events was 8 percent or fewer in each period.
- What it means: For a patient weighing the FLAURA2 regimen against osimertinib alone, the extra toxicity is front-loaded: the hardest months are the four induction cycles, and once pemetrexed stops the profile returns to that of osimertinib by itself. Kidney function deserves watching during pemetrexed maintenance.
- Caveats: Post hoc analysis of one arm; the periods are defined by each patient's exposure, so those who reached the later periods were by construction the ones who tolerated the earlier ones.; Onset frequencies count new events in each period and are not directly comparable with the trial's overall safety tables.

## Sources

- Lung Cancer 2026: https://doi.org/10.1016/j.lungcan.2026.109588
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42728193/
- ClinicalTrials.gov NCT04035486: https://clinicaltrials.gov/study/NCT04035486

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lines of therapy](https://onco.cc/terms/first-line/)
- trials: [FLAURA2](https://onco.cc/trials/flaura2/)
- people: [David Planchard](https://onco.cc/people/david-planchard/), [Pasi A. Jänne](https://onco.cc/people/pasi-janne/)
- journals: [Lung cancer](https://onco.cc/journals/lung-cancer-journal/)

---
JSON: https://onco.cc/api/v1/entities/paper-flaura2-long-term-safety-lung-cancer-2026.json